Work

Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Year: 2022

Type: article

Source: Leukemia

DOI: 10.1038/s41375-022-01699-7

Authors: Shenmiao Yang, Neil E. Kay, Min Shi, Curtis A. Hanson, Robert Peter Gale

Institutions: Peking University People's Hospital, Mayo Clinic, Imperial College London

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4295757909

FWCI: 0.634

Cites: 65

Cited by: 5

Related to: 10